Company Filing History:
4 out of 205 
3 out of 1,744 
1 out of 1 Years Active: 2018-2025
Title: Monique Vallee: Innovator in Cannabinoid-Related Treatments
Introduction
Monique Vallee is a prominent inventor based in Bordeaux, France. She has made significant contributions to the field of cannabinoid-related disorders through her innovative research and patented inventions. With a total of 4 patents, Vallee's work focuses on developing compounds that can effectively inhibit the effects of THC.
Latest Patents
One of her latest patents is for the compound 3β-(4-methoxybenzyloxy)pregn-5-en-20-one, which is designed for use in the treatment of cannabinoid-related disorders. This invention relates to a specific pregnenolone derivative that has shown potent in vivo effects in inhibiting THC. It is capable of reducing both unconditioned and conditioned effects of THC, including self-administration and reinstatement in THC-seeking behavior in non-human primates. Another notable patent involves 3-(4'-substituted)-benzyl-ether derivatives of pregnenolone, which includes a compound of Formula (I) that can be used as a pharmaceutically acceptable salt.
Career Highlights
Throughout her career, Monique Vallee has worked with esteemed institutions such as Université de Bordeaux and the Institut National de la Santé et de la Recherche Médicale. Her research has been pivotal in advancing the understanding and treatment of cannabinoid-related disorders.
Collaborations
Vallee has collaborated with notable colleagues, including Pier Vincenzo Piazza and Jean-Michel Revest, contributing to a rich exchange of ideas and research in her field.
Conclusion
Monique Vallee's innovative work in cannabinoid-related treatments showcases her dedication to advancing medical science. Her patents reflect her commitment to finding effective solutions for complex health issues.